Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fusion-TAC
- Development stage
- Unknown
- Lead developer
- ViferaXS
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous, Injection
01
Overview
Fusion-TAC is a T-cell activating immunotherapy developed by ViferaXS for the treatment of Fibrolamellar Carcinoma (FLC). The drug is designed to direct the immune system, specifically T cells, against neoepitopes derived from the unique fusion proteins characteristic of Fibrolamellar Carcinoma, such as the DNAJB1-PRKACA fusion. By targeting these tumor-specific neoantigens, Fusion-TAC aims to induce a potent and selective anti-tumor immune response. It is currently being evaluated in Phase 1/2 clinical trials.
02
Targets
pMHC (Peptide-MHC complex family)DNAJB1-PRKACA (DNAJ heat shock protein family member B1-protein kinase cAMP-dependent catalytic subunit alpha fusion protein)
Beyond the preview
Go deeper on Fusion-TAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fusion-TAC.